"Cetylpyridinium" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges.
| Descriptor ID |
D002594
|
| MeSH Number(s) |
D03.383.725.762.232
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cetylpyridinium".
Below are MeSH descriptors whose meaning is more specific than "Cetylpyridinium".
This graph shows the total number of publications written about "Cetylpyridinium" by people in this website by year, and whether "Cetylpyridinium" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Cetylpyridinium" by people in Profiles.
-
Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. J Dent Res. 2021 10; 100(11):1265-1272.
-
Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters. J Pharmacol Exp Ther. 2021 10; 379(1):96-107.
-
Oral antiseptics against coronavirus: in-vitro and clinical evidence. J Hosp Infect. 2021 Jul; 113:30-43.
-
Use of mouthwashes in the management of COVID-19 patients in intensive care units: recommendations and current evidence. Einstein (Sao Paulo). 2021; 19:eCE6419.
-
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Sci Data. 2021 02 26; 8(1):70.
-
Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2021 Apr; 49(2):305-311.
-
Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 2017 01 14; 17(1):74.